# Leqembi: Two Years of Commitment in Alzheimer’s Care

Newsy: Alzheimer’s News Weekly
Published: 2026-03-23T13:30:00.272Z
Source: https://newsyai.com/edition/aaad9c18-c94f-4f3c-9eba-28fce1eec5fc
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
**Coverage period: March 17–March 23, 2026**

Below are this week’s most meaningful, truly **new** developments, ranked by impact on treatment and access.

**1. Real-world data shows most patients stick with Leqembi treatment for two full years**  
- **Overview**  
  New analysis from U.S. patient records shared at the AD/PD conference revealed that 78% of people with early Alzheimer’s kept using Leqembi (lecanemab) at 18 months, dropping to 67% at 24 months. This high "stickiness" matches lab study extensions where benefits lasted four years.[[1]](https://www.prnewswire.com/news-releases/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpd-congress-302721848.html)  
- **Why this matters**  
  Long-term use is key to slowing the disease like buying time before a storm hits harder; proving everyday patients can handle it for years builds doctor confidence and encourages early starts, unlike worries from shorter studies.

**2. Scientists uncover exactly how Leqembi clears brain plaques using the immune system**  
- **Overview**  
  A new study explains Leqembi works not just by sticking to sticky plaques (amyloid), but by its "tail" part (Fc fragment) signaling the brain's cleanup crew (microglia) to gobble them up like Pac-Man eating dots. Without this tail signal, it fails completely.[[2]](https://www.sciencedaily.com/releases/2026/03/260317064457.htm)  
- **Why this matters**  
  Knowing the "how" opens doors to simpler drugs that directly wake the cleanup crew without big antibodies, potentially cheaper and easier shots—turning plaque removers into smarter, targeted helpers.

**3. New tech boosts brain delivery of plaque-targeting drug, with early signs of brain protection**  
- **Overview**  
  Acumen Pharma showed at AD/PD how they fused their plaque-oligomer hunter (sabirnetug) with a brain-door opener, getting more drug inside mouse brains without losing aim. Phase 1 human tests also spotted helpful shifts in blood markers for twisted proteins and brain stress.[[3]](https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain)  
- **Why this matters**  
  The blood-brain wall blocks many drugs like a fortress gate; cracking it means stronger plaque attacks inside, plus markers to track if it's working—speeding better versions of today's treatments.

**4. Sticky plaques hijack twisted protein's helpful job inside brain cells**  
- **Overview**  
  Fresh lab work reveals amyloid plaques sneak inside neurons and shove tau (twisted proteins) off transport tracks (microtubules), messing up nutrient delivery and sparking tau tangles—like traffic jams from a rude driver cutting in.[[4]](https://news.ucr.edu/articles/2026/03/18/key-alzheimers-proteins-are-competing-inside-brain-cells)  
- **Why this matters**  
  Shifts view from outside clumps to inside chaos; drugs blocking amyloid's sneaky entry or gluing tau back could prevent tangles early, complementing plaque-clearers for fuller protection.

**5. Brain connection markers in spinal fluid predict fast decline better than others**  
- **Overview**  
  Low levels of NPTX1 and NPTXR (synaptic proteins signaling healthy brain links) in spinal fluid warn of quicker brain shrinkage and thinking drop in early Alzheimer’s, spotting who advances from mild issues to dementia with 80% accuracy—better than plaque or tau checks.[[5]](https://www.alzforum.org/news/research-news/can-synaptic-markers-forecast-worsening-alzheimers-disease)  
- **Why this matters**  
  Like a dashboard warning light for brain wiring fraying (what causes memory loss), it picks perfect trial patients or early treatment candidates, ensuring drugs hit those who need them most.

## What this means for care right now
- **Boost Leqembi confidence**: High persistence proves it's doable long-term—ask about it if early stage.[[1]](https://www.prnewswire.com/news-releases/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpd-congress-302721848.html)  
- **Track combo advances**: Better delivery (Acumen) and mechanisms (Leqembi) pave for next-gen plaque fighters.[[3]](https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain)[[2]](https://www.sciencedaily.com/releases/2026/03/260317064457.htm)  
- **Use smart markers**: Synaptic checks + amyloid/tau for precise starts; watch tau delivery drugs like BMS-986446.[[5]](https://www.alzforum.org/news/research-news/can-synaptic-markers-forecast-worsening-alzheimers-disease)[[6]](https://ir.prothena.com/investors/press-releases/news-details/2026/Prothena-Partners-Present-Data-Supporting-Next-Generation-Treatments-for-Parkinsons-and-Alzheimers-Disease-at-ADPD-2026/default.aspx)  
- **Inside cell fixes**: Amyloid-tau rivalry hints at new pills protecting transport rails.

## Sources
- Leqembi persistence (March 23, 2026), [PRNewswire](https://www.prnewswire.com/news-releases/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpd-congress-302721848.html)[[1]](https://www.prnewswire.com/news-releases/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpd-congress-302721848.html)  
- Leqembi mechanism (March 17, 2026), [ScienceDaily](https://www.sciencedaily.com/releases/2026/03/260317064457.htm), *Nature Neuroscience*[[2]](https://www.sciencedaily.com/releases/2026/03/260317064457.htm)  
- Acumen sabirnetug EBD & biomarkers (March 17, 2026), [Acumen Investors](https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain)[[3]](https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain)  
- Amyloid-tau competition (March 18, 2026), [UCR News](https://news.ucr.edu/articles/2026/03/18/key-alzheimers-proteins-are-competing-inside-brain-cells)[[4]](https://news.ucr.edu/articles/2026/03/18/key-alzheimers-proteins-are-competing-inside-brain-cells)  
- Synaptic markers (March 19, 2026), [Alzforum](https://www.alzforum.org/news/research-news/can-synaptic-markers-forecast-worsening-alzheimers-disease), *Nature Communications*[[5]](https://www.alzforum.org/news/research-news/can-synaptic-markers-forecast-worsening-alzheimers-disease)  

If a week brings few blockbuster trial results, focus stays on building blocks for better care.
